Skip to main content

Table 3 Different disease and duration of response

From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Pathological diagnosis Target therapy protocol Patients number (N) Best responsea Median (average) DR (months)
Osteosarcoma Apatinib alone 22 PR 3.1 (3.7)
Ewing sarcoma Apatinib + everolimus & apatinib alone 10 PR 1.5 (3.3)
Synovial sarcoma Apatinib alone 6 PR 5.2 (5.8)
MPNSTc Apatinib alone 3 PR 8.8 (10.1)
Epithelioid sarcoma Apatinib + GTb 2 PR (4.7)
UPSd Apatinib alone 4 PR 5.6 (5.0)
Fibrosarcoma Apatinib alone 1 PR 2.7
Chondrosarcoma Apatinib alone 3 PR (7.4)
ASPSe Apatinib + GTb 3 PR (7.4)
Extraskeletal osteosarcoma Apatinib alone 1 SD 6.6
Mucinous type liposarcoma Apatinib alone 1 PD 1.0
  1. aPR partial response, SD stable disease according to RECIST 1.1
  2. bGT chemo-protocol combined with gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8
  3. cMPNST malignant peripheral nerve sheath tumor
  4. dUPS undifferentiated pleomorphic sarcoma
  5. eASPS alveolar soft part sarcoma